Miracle drug’ can cost Rs 13 lakh for haemophilia A patient annually, but reduced dose found efficacious & cost-effective in ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...

A new study found that patients with hemophilia A could safely switch directly from emicizumab to Mim8 without a washout period, meaning they did not need to stop treatment before starting the new ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating ...

The first haemophilia B patient in Germany has been treated with the one-time gene therapy HEMGENIX at the Hemophilia Treatment Center at Hannover Medical School, CSL Behring Germany has announced.

Novo Nordisk NVO announced new data from the phase III FRONTIER clinical program, comprising five separate studies evaluating ...

Pfizer has reported positive topline outcomes from the multicentre, open-label Phase III BASIS trial of Hympavzi (marstacimab) for adults and adolescents with haemophilia A or B with inhibitors. The ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Primary and secondary end points were demonstrated in a phase 3 trial of subcutaneous marstacimab as treatment for patients ...

Factor IX, and FEIBA (Anti-Inhibitor Coagulant Complex), which are critical for preventing fatal bleeds in patients with the ...

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...